Physician

Lisa C Thomas, MD

According to 2025 Medicare claims, Lisa Thomas, MD (NPI: 1346239894) practices hematology/oncology in the Scranton--Wilkes-Barre, PA market, with the plurality of this provider's patient population coming from Lackawanna, PA. This provider's primary affiliated billing organization is HEMATOLOGY AND ONCOLOGY ASSOCIATES OF NORTHEASTERN PA, PC (NPI: 1164538724; TIN: 232137083) and primary practice location at 18512-3169. Thomas is affiliated with the Keystone ACO (ACO ID: A1552), participating under the MSSP model.

Thomas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 958 traditional Medicare patients, billed 231,526 HCPCS/CPT codes, and received $3,402,240 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,378 prescription claims across 288 beneficiaries totaling $3,077,062 in drug costs, led by Ibrance (Palbociclib). DME data shows 190 claims. Open Payments data shows 10 records totaling $3,445. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,636,173 to $3,402,240. Similarly, Part D prescription costs have moved sharply higher in recent years, from $951,756 to $3,077,062. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	812	160,119	$1,636,173
2016	832	272,574	$1,911,936
2017	841	288,435	$2,258,710
2018	891	256,433	$2,677,185
2019	890	233,459	$2,781,118
2020	932	221,549	$2,245,115
2021	962	212,872	$2,425,849
2022	1,078	225,396	$2,566,420
2023	1,027	199,993	$2,437,211
2024	958	231,526	$3,402,240

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	234	1,294	$951,756
2016	264	1,422	$1,120,334
2017	268	1,538	$998,012
2018	276	1,462	$733,881
2019	273	1,345	$1,197,947
2020	216	1,049	$1,089,391
2021	250	1,069	$1,758,154
2022	272	1,166	$3,159,654
2023	292	1,353	$3,531,867
2024	288	1,378	$3,077,062

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	46	$32,071
2016	N/R	82	$24,400
2017	N/R	84	$18,256
2018	N/R	56	$6,801
2019	N/R	N/R	N/R
2020	N/R	40	$617
2021	11	106	$5,941
2022	N/R	102	$3,696
2023	24	156	$32,565
2024	N/R	190	$4,602

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	331	921	$128
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	627	1,081	$87
80053	Blood test, comprehensive group of blood chemicals	801	2,490	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	802	2,728	$8
83540	Iron level	326	786	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	57	1,596	$782,530
Tasigna	Nilotinib Hcl	19	532	$374,131
Imbruvica	Ibrutinib	19	532	$287,339
Cabometyx	Cabozantinib S-Malate	14	420	$269,233
Lenalidomide	Lenalidomide	23	630	$266,280

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	53	$2,320
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	54	$997
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	21	$629
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	37	$502
J8520	Capecitabine, oral, 150 mg	N	N/R	25	$154

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$3,445	Incyte Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Lisa C. Thomas, MD?

Tedicare shows public-source Medicare data for Lisa C. Thomas, MD (NPI 1346239894), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lisa C. Thomas, MD have ACO affiliation data?

Lisa C. Thomas, MD is shown with ACO affiliation data for Keystone ACO (MSSP, ACO ID A1552).

What billing organization is linked to Lisa C. Thomas, MD?

Lisa C. Thomas, MD is linked to HEMATOLOGY AND ONCOLOGY ASSOCIATES OF NORTHEASTERN PA, PC (billing NPI 1164538724) in the available physician profile data.

Does Lisa C. Thomas, MD have Open Payments data?

Lisa C. Thomas, MD has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.